InvestorsHub Logo
Followers 0
Posts 25
Boards Moderated 0
Alias Born 02/18/2023

Re: None

Monday, 08/28/2023 8:46:56 AM

Monday, August 28, 2023 8:46:56 AM

Post# of 3015
When Xocova and Atea's Sunrise comes out in U.S. market on 2024 or 2025. It will probably be before EDP-235's roll out.

Would it be weird thinking like one of each could substitute Paxlovid? Then EDP-235 wouldn't get as much market space to penetrate?

IMO, it is ritonavir that the most serious issue of Paxlovid. And both of them don't have ritonavir as far as I've seen.

Plus, EDP-514 has higher EC50 than Aligos drug, which means it has a less effective result as I understood. What do you think we could expect from this HBV treatment's result?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News